BCL2 (B-cell CLL/lymphoma 2)

P=N/A, N=35, Active, not recruiting, Alexion Pharmaceuticals, Inc. | Trial completion date: Sep 2026 --> Aug 2027 | Trial primary completion date: Sep 2026 --> Aug 2027

This study first demonstrates juglone's anti-OS efficacy via the ROS/PI3K/AKT pathway. In vivo studies confirm potent tumor suppression with short-term safety, supporting its clinical promise for OS treatment.

This review provides a comprehensive overview of the current in vitro evidence supporting the anticancer potential of CAS, with a particular focus on its molecular mechanisms of action. The multifaceted nature of CAS activity highlights its promise as a potential adjunct or alternative in future cancer therapies.

This study demonstrated that synthetic eugenol derivatives potentiated the effects of docetaxel in prostate cancer cells. Further research is necessary to elucidate the underlying mechanisms and to better understand its clinical advantages in prostate cancer therapy.

Furthermore, corynoline treatment significantly inhibited the growth of GBM in vivo and was shown to modulate the STAT3/Bcl-2 signalling pathway. These results suggest that corynoline exerts antitumour activity against GBM by inhibiting the STAT3/Bcl2 pathway, indicating that corynoline might be a promising agent for the treatment of GBM.

These findings were further supported by DFT calculations, molecular electrostatic potential mapping, frontier molecular orbital analysis, in silico ADMET predictions, and molecular dynamics. Taken together, catechin and 6S,9S-roseoside emerge as promising candidates for anticancer and antioxidant drug development.

The patient was given R-CHOP chemotherapy and intrathecal methotrexate with a favorable early response...Image-guided biopsy and immunophenotyping at an early stage are crucial to avoid misdiagnosis and guide appropriate therapy. Individualized and risk-adapted approaches are crucial in maximizing the outcome in such aggressive and rare presentations.

Moringa's diverse mechanisms, broad-spectrum activity, and low toxicity underscore its potential as an adjunct in cancer therapy. Future research should focus on clinical validation, standardized formulations, delivery systems, understudied cancers, and combinatorial regimens with conventional therapies to advance its role in integrative oncology.

Histopathological findings further confirmed that boldine preserved renal tissue integrity and prevented tubular and glomerular damage. Overall, boldine significantly protected against 5-FU-induced renal injury via anti-apoptotic, antioxidant, and anti-inflammatory mechanisms.

NG attenuated the adverse effects of LPS challenge on intestinal barrier function and enhanced antioxidant capacity in broilers by modulating intestinal tight junction expression and antioxidant enzyme activity. NG may serve as a promising eco-friendly additive to enhance resilience against immune stress in broilers.

These findings demonstrate that OTA selectively targets healthy immune cells rather than leukemia cells, highlighting its pronounced immunotoxic risk and the importance of caution when considering its effect in a hematological context. Although limited to in vitro models, this study underscores the necessity of further research to clarify the molecular basis of differential OTA sensitivity and its contribution to immunosuppression and hematological disease.

TMA-based DSP is feasible in archival breast tissues and yields biologically coherent, cross-platform-benchmarked profiles that are particularly robust in BC, while conserving scarce TDLUS and clarifying current limits of single-marker risk stratification from benign lobules. These data provide a foundation for refined sampling and expanded panels in future TDLU-focused studies.